- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04252690
Physiological Study to Assess Mechanism of Action of MOBIDERM® in Lower-limb Lymphedema Patients (ACTIODERM)
MOBIDERM® demonstrated his interest through clinical studies on the treatment of lower or upper limb lymphedema (Mestre et al 2017; Quéré et al. 2014). This CE (Conformity European)-marking device is well established both in ambulatory and hospitalisation. Nevertheless, the mechanism of action of this device had never been confirmed and no experimental clinical studies had been performed. The hypothesis is that the MOBIDERM system creates a pressure differential between the contact zone underneath the foam cubes composing the system and their surrounding area, leading to a shear effect on the subcutaneous tissues treated.
The aim of this study is thus to assess the mechanism of action of MOBIDERM on the lymphatic system by evaluating quantitative and qualitative effects of this medical device on lymphatic system, oedema volume and cutaneous parameters in 10 lymphoedema patients during their hospitalisation for reduction phase.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Astrid PICOLET, CRA
- Phone Number: +33 4 77 81 67 96
- Email: astrid.picolet@thuasne.fr
Study Contact Backup
- Name: Stephanie VILLET, PhD
- Phone Number: +33 6 47 78 04 29
- Email: stephanie.villet@thuasne.fr
Study Locations
-
-
-
Tours, France, 37044
- CHRU Tours
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Primary or secondary lower limb lymphedema of stage 2 or 3 according to the criteria defined by International Society of Lymphology
- Affected leg that fits with one of the standard sizes of the Auto-Adjustable MOBIDERM® Autofit stocking provided
- Signed informed consent prior to any study-mandated procedure.
Exclusion Criteria:
- Pregnant or breastfeeding patient
- Childbearing age patient without contraception
- Intolerance to Mobiderm or known allergy to the components used
- Evolutive lower limb infection
- Acute lower limb inflammation
- Dermatological ailment oozing from the treated limb
- Severe medical condition that may interfere with the proper conduct of the study
- Advanced diabetic microangiopathy
- Limb arteritis stage III or IV
- Decompensated heart failure
- Involvement in another clinical study
- Patient mentally incapable of understanding the nature, objectives and possible consequences of the study and / or refusing to submit to the constraints of this trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mobiderm
MOBIDERM® autofit : auto-adjustable compression stocking
|
The experimental protocol will require 2 visits during usual reduction phase performed at the hospital (5 days of hospitalization). Visit 1 will be performed the first day of hospitalization and will consist of inclusion visit and some evaluations (lymphoscintigraphy, edema volume, cutaneous characteristics). Between visit 1 (D1) and visit 2 (D3), patients will wear Mobiderm Autofit continually. Visit 2 will be performed the third day of hospitalization and will consist of evaluations (lymphoscintigraphy, edema volume, cutaneous characteristics, satisfaction survey). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline extraction rates at 3 days after wearing MOBIDERM
Time Frame: Day : 3
|
Assess the difference of extraction rate (%) in different areas (ankle, upper and lower middle third of the leg, knee, calf) by lymphoscintigraphy performed at D1 and D3 after wearing MOBIDERM®
|
Day : 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of vascular lymphatic activity between D1 and D3
Time Frame: Day : 3
|
Assess change of vascular lymphatic activity based on qualitative data (activity YES/NO ; quality of activity : usual - semi usual - unusual) obtained during dynamic acquisition of lymphoscintigraphy from baseline to D3
|
Day : 3
|
Change of lymphatic vascular flow between D1 and D3
Time Frame: Day : 3
|
Assess change of amplitude vascular flow : important - medium- weak ; and of flow velocity : normal, slow, inexistent from baseline to D3
|
Day : 3
|
Change on lymphatic system between D1 and D3 : short term effect
Time Frame: Day : 3
|
Assess change on lymphatic system from baseline to D3 (short term effect) , based on quantitative data : number of lympho node fixation ; and qualitative data: lympho node fixation intensity : important - medium - low ; tortuous appearance of the lymphatic vessels : YES/NO ; presence of collateral : YES/NO ; presence of dermal reflux : YES/NO ; presence of popliteal ganglion : YES/NO.
|
Day : 3
|
Change on lymphatic system between H2 and H4 : immediate effect
Time Frame: Hours : 2 and 4
|
Assess change on lymphatic system from baseline to 2 and 4 hours : immediate effect, based on quantitative data : number of lympho node fixation ; and qualitative data: lympho node fixation intensity : important - medium - low ; tortuous appearance of the lymphatic vessels : YES/NO ; presence of collateral : YES/NO ; presence of dermal reflux : YES/NO ; presence of popliteal ganglion : YES/NO.
|
Hours : 2 and 4
|
Lymphedema volume reduction between D1 and D3
Time Frame: Days : 1 and 3
|
Leg perimeters (cm) of 7 part of leg will be measured (ankle, patella, +10cm +20cm +30cm and -10cm -20cm and -30cm of patella).
Based on truncated cone formula, volume (mL) of each leg will be calculated.
These volumes will be compared between D1 and D3 in order to assess lymphedema volume reduction.
|
Days : 1 and 3
|
Skin condition evolution between D1 and D3
Time Frame: Days : 1 and 3
|
Skin condition will be assessed by cutaneous ultrasound scan (skin thickness (mm) , skin echogenicity (hypoechogenicity - isoechogenicity, hyperechogenicity) , oedema distribution in the dermis (superficial dermis - deep dermis - overall of dermis -hypodermis and dermis) performed on 3 areas : ankle, leg and thigh.
Skin condition evolution will be assessed at D1 and D3.
|
Days : 1 and 3
|
Cutaneous suppleness between D1 and D3
Time Frame: Days : 1 and 3
|
Cutaneous suppleness evolution is assessed with a cutometer.
Cutaneous suppleness is described by skin elasticity, elastic capacity and viscoelasticity.
Cutometer measurements are expressed in millimetre (skin deformation, skin relaxation, skin extensibility) and will be presented as quantitative data.
|
Days : 1 and 3
|
Number of type of serious and non-serious Adverse Device Effects
Time Frame: Day : 3
|
Number and type of serious and non-serious Adverse Device Effects (ADE) will be reported during the study
|
Day : 3
|
Satisfaction regarding MOBIDERM
Time Frame: Day : 3
|
Satisfaction is measured by a satisfaction questionnaire wrote specifically for the study.
This questionnaire is focused on positioning the product, comfort, esthetic and global satisfaction.
|
Day : 3
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Loïc VAILLANT, MD, University Hospital of Tours
Publications and helpful links
General Publications
- Quere I, Presles E, Coupe M, Vignes S, Vaillant L, Eveno D, Laporte S, Leizorovicz A; POLIT Study investigators. Prospective multicentre observational study of lymphedema therapy: POLIT study. J Mal Vasc. 2014 Jul;39(4):256-63. doi: 10.1016/j.jmv.2014.05.004. Epub 2014 Jun 12.
- Mestre S, Calais C, Gaillard G, Nou M, Pasqualini M, Ben Amor C, Quere I. Interest of an auto-adjustable nighttime compression sleeve (MOBIDERM(R) Autofit) in maintenance phase of upper limb lymphedema: the MARILYN pilot RCT. Support Care Cancer. 2017 Aug;25(8):2455-2462. doi: 10.1007/s00520-017-3652-5. Epub 2017 Mar 9.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EC18
- ANSM (Other Identifier: 2022-A02513-40)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphedema, Secondary
-
Tactile MedicalVanderbilt University Medical CenterRecruitingLymphedema | Lymphedema, Secondary | Lymphedema; Surgical | Lymphedema of Face | Lymphedema Due to RadiationUnited States
-
Lymphatica Medtech SATerminatedLymphedema of Upper Limb | Lymphedema, Secondary | Lymphedema, Lower Limb | Lymphedema of Leg | Lymphedema ArmSwitzerland
-
Inland Norway University of Applied SciencesMontebellosenteret, Mesnali, NorwayCompletedLymphedema, SecondaryNorway
-
University Hospital, MontpellierCompletedPrimary Lymphedema Secondary LymphedemaFrance
-
ResMedLymphatic Solutions, LLCCompletedLymphedema | Lymphedema, Secondary | Lymphedema, Lower Limb | Lymphedema of Leg | Lymphedema PrimaryUnited States
-
Our Lady of the Lake HospitalCompletedSecondary Lymphedema | Lymphedema of FaceUnited States
-
Maastricht University Medical CenterRadboud University Medical Center; Erasmus Medical CenterRecruitingLymphedema of Upper Limb | Lymphedema, Secondary | Lymphedema, Lower Limb | Lymphedema of Leg | Lymphedema ArmNetherlands
-
Isabel Forner-Cordero, MD, PhD.CompletedSecondary Lymphedema | Primary LymphedemaSpain
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)RecruitingLymphedema, Secondary | Lymphedema of Leg | Lymphedema Related FibrosisUnited States
-
Vanderbilt University Medical CenterNational Institute of Nursing Research (NINR); National Institutes of Health...Recruiting
Clinical Trials on MOBIDERM® autofit : auto-adjustable compression stocking
-
ThuasneCompleted
-
ThuasneInternational Clinical Trials AssociationRecruitingLymphedema of Upper ArmFrance, Turkey
-
Nij Smellinghe HosptialCompleted